Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics' stock price has been impacted by positive clinical data from ELVN-001, financial reporting indicating a strong cash position, presentations at healthcare conferences, and industry validation from Merck's acquisition of Terns Pharmaceuticals. There have also been reports of insider selling. The stock price has seen significant increases, with a 174.50% increase between April 11, 2025, and April 8, 2026.

Enliven Therapeutics, Inc. does not currently have commercialized products or services, so there is no discernible demand seasonality. The company's focus is on the discovery and development of therapeutics, with products still undergoing clinical trials.

Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule inhibitors for cancer treatment, operating within the Biotechnology industry. The company aims to address unmet medical needs through precision oncology, focusing on therapies that improve patient survival and well-being. Enliven is advancing two primary product candidates: ELVN-001, a kinase inhibitor targeting the BCR-ABL gene fusion for CML, and ELVN-002, a HER2 inhibitor for NSCLC and other HER2 mutant tumors.

Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, USA. While the company's operational footprint is primarily based in the United States, its institutional ownership indicates a significant presence of investors from the US and the UK.

Enliven Therapeutics has maintained a positive brand reputation due to promising clinical developments and positive analyst sentiment. Positive clinical trial results for ELVN-001 and analyst endorsements have contributed to this reputation. The acquisition of Terns Pharmaceuticals by Merck also boosted confidence in Enliven's ELVN-001. The company's strong cash position also contributes to a stable reputation. However, insider selling could potentially raise concerns among investors.

Enliven Therapeutics, Inc. has significant institutional ownership, with 125 institutional owners and shareholders holding a total of 60,700,939 shares as of April 8, 2026. Institutional shareholders own 104.19% of the stock, while Enliven Therapeutics insiders own 101.14%. Orbimed Advisors LLC is the largest individual shareholder.